Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Sinovac Biotech Ltd. (NASDAQ:SVA), a developer of vaccines to treat hepatitis A, hepatitis B, and various strains of influenza, spiked higher by as much as 12% after the company reported second-quarter earnings results.
So what: For the quarter, Sinovac delivered a huge jump in revenue of 86.4% to $17.5 million driven by a doubling in hepatitis A vaccine sales, and a 58% increase in hepatitis B vaccine revenue. The company also managed to reverse a year-ago loss of $0.03 per share into a $0.02 per share profit. Comparatively, these results crushed the Street's lone estimate, which had called for an EPS loss of $0.02 on $11.6 million in revenue. Looking ahead, the company is expecting big things from its hand, foot, and mouth disease (HFMD) vaccine EV71, which is currently being reviewed by the China Food and Drug Administration.
Now what: I have to hand it to Sinovac; that was a really impressive quarter. I've been somewhat downbeat on Sinovac primarily due to the hype surrounding its HFMD vaccine EV71 which could fall flat on its face if the Chinese government chooses not to make a big enough purchase of the vaccine to make it profitable for Sinovac. All the while, I forgot all about the company's growing hep A and hep B vaccines. Personally, I'd like to see if Sinovac can keep its hepatitis vaccine momentum going in the upcoming quarters before jumping on board with the optimists. Waiting on the sidelines should also allow the hype around EV71 to mellow into more realistic expectations.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.